A Population-Based Nested Case-Control Study in Taiwan: Use of 5α-Reductase Inhibitors Did Not Decrease Prostate Cancer Risk in Patients with Benign Prostate Hyperplasia

BACKGROUND. 5α-Reductase inhibitors (5ARIs) are commonly used to treat benign prostate hyperplasia (BPH) by blocking the conversion of testosterone into the more potent dihydrotestosterone. This study explored a possible association between the use of the 5ARIs finasteride and dutasteride and the su...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Liang, Ji-An, Sun, Li-Min, Lin, Ming-Chia, Chang, Shih-Ni, Sung, Fung-Chang, Muo, Chih-Hsin, Kao, Chia-Hung
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Outcomes Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399656/
https://ncbi.nlm.nih.gov/pubmed/22723508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0464
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky